Novartis begins tender offer for cancer-focused MorphoSys: Novartis said on Thursday it has launched a tender offer to acquire MorphoSys ...
reuters.com/business/healthcare-pharmaceuticals/novartis-begins-tender-offer-morphosys-2024-04-11/
How Novartis Rode Two Blockbusters To A Three-Day Sprint: Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts ...
investors.com/news/technology/novartis-stock-novartis-earnings-q1-2024/
Quick Glance: Positive Quarterly Results Lead to Guidance Increase at Novartis
- Novartis raises its annual guidance following a successful first quarter.
- Revenue increased by 10% to $11.83 billion, with adjusted operating income growing by 16% to $4.54 billion.
- CEO Vas Narasimhan is focusing more on drug development and has been active in mergers and acquisitions.
- Novartis has secured promising drugs, including an experimental prostate cancer drug from Arvinas and the company MorphoSys, which develops cancer treatments, for 2.7 billion euros.
Novartis enters into licensing deal for Arvinas’ cancer drug worth up to $1.01 billion
financialexpress.com/healthcare/pharma-healthcare/novartis-enters-into-licensing-deal-for-arvinas-cancer-drug-worth-up-to-1-01-billion/3454058/
FDA Approves First Drug That Can Reduce Allergic Reaction After Exposure to Food Allergens
healthline.com/health-news/fda-approves-first-drug-that-can-reduce-allergic-reaction-after-exposure-to-food-allergens
Novartis acquires German biotech MorphoSys for CHF2.5 billion: Even after its numerous acquisitions in 2023, the pharmaceutical company Novartis has not yet ...
swissinfo.ch/eng/business/novartis-acquires-german-biotech-morphosys-for-chf2_5-billion/49189882
FDA Approves Drug to Reduce Accidental Food Allergies: The new indication makes Xolair (omalizumab) the first drug approved to mitigate allergic reactions to ...
medscape.com/viewarticle/fda-approves-drug-reduce-accidental-food-allergies-2024a10003b3
Paid articlePaid
UK's MHRA revokes authorisation for Novartis' sickle cell drug: Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation ...
reuters.com/business/healthcare-pharmaceuticals/uks-mhra-revokes-authorisation-novartis-sickle-cell-drug-2024-02-21/
Novartis makes progress with myeloid leukaemia drug: Swiss pharma Novartis sees clinical trial superiority of Scemblix for Philadelphia chromosome-positive ...
swissinfo.ch/eng/sci-tech/novartis-makes-progress-with-myeloid-leukaemia-drug/49109142
FDA Approves First Medication For Treating Allergic Reactions To Multiple Foods: The injectable drug is not approved for “immediate emergency treatment of ...
forbes.com/sites/caileygleeson/2024/02/16/fda-approves-first-medication-for-treating-allergic-reactions-to-multiple-foods/
CML: 'You have to educate yourself so that you can be your own advocate'
cmladvocates.net/2023/12/11/you-have-to-educate-yourself-so-that-you-can-be-your-own-advocate/
US FDA investigating safety risk of CAR-T cancer therapies: The U.S. Food and Drug Administration (FDA) said on Tuesday it was investigating cancer therapies ...
reuters.com/legal/government/us-fda-investigating-safety-risk-car-t-cancer-therapies-2023-11-28/
Corona theater shooter claims voices prompted him to kill 2 teens: Joseph Jimenez testified Monday in his insanity trial that will send him either to prison or a ...
pressenterprise.com/2023/12/04/corona-theater-shooter-claims-voices-prompted-him-to-kill-2-teens/
The Aftermath of a 'Miracle Cure' for a Rare Cancer: In 2001, Gleevec was approved as a treatment for chronic myelogenous leukemia. It was a revelation for ...
wired.com/story/tyranny-of-the-gene-james-tabery-excerpt/
What happens when a $3m gene therapy is not enough: It has raised broader questions around high-cost gene therapies entering the market ...
straitstimes.com/world/united-states/what-happens-when-a-3m-gene-therapy-is-not-enough
That's how ill Germany's students are: Head- and back pain, concentration and sleep problems - Significantly more students are reporting this today than in 2015 ...
zm-online.de/news/detail/so-krank-sind-deutschlands-studierende
Novartis' Sandoz wagers its standalone future on biosimilar success: Novartis' (NOVN.S) soon-to-be spun off generics division Sandoz is betting on biosimilars ...
reuters.com/business/healthcare-pharmaceuticals/novartis-sandoz-generate-additional-3-bln-net-sales-over-next-five-years-2023-06-08/
'Huge breakthrough': The new vitiligo cream that could soon be available on the NHS
itv.com/news/2023-03-08/huge-breakthrough-the-new-vitiligo-cream-that-could-soon-be-available-on-nhs
CART-T cell therapies for cancer: Kite steals the show from Novartis: The mostly young employees at Kite Pharma's Dutch factory are highly motivated ...
nzz.ch/wirtschaft/zelltherapien-versprechen-krebskranken-neue-hoffnung-aber-die-herstellung-ist-noch-viel-zu-aufwendig-ld.1727465
USFDA approves Novartis’ combination targeted therapy for pediatric brain cancer: These data were highlighted as part of an official press briefing and oral ...
financialexpress.com/healthcare/pharma-healthcare/usfda-approves-novartis-combination-targeted-therapy-for-pediatric-brain-cancer/3012897/
Houghton heart donor honoured for giving the gift of life: A woman who donated her heart, giving life to another human being, has been honoured posthumously at a ...
sunderlandecho.com/news/people/houghton-heart-donor-honoured-for-giving-the-gift-of-life-4043713
Paid articlePaid Novartis’ investigational drug shows positive outcomes in patients with rare blood disorder
financialexpress.com/healthcare/pharma-healthcare/novartis-investigational-drug-shows-positive-outcomes-in-patients-with-rare-blood-disorder/2905916/
Generic drugmakers Teva and Sandoz make major push to biosimilars: Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a ...
reuters.com/business/healthcare-pharmaceuticals/generic-drugmakers-teva-sandoz-make-major-push-biosimilars-2022-11-22/
Novartis’ bad cholesterol drug shows ‘sustained’ efficacy and safety among cardiac patients
financialexpress.com/healthcare/pharma-healthcare/novartis-bad-cholesterol-drug-shows-sustained-efficacy-and-safety-among-cardiac-patients/2787571/
Novartis’ investigational oral monotherapy shows positive results against rare blood disease
financialexpress.com/healthcare/pharma-healthcare/novartis-investigational-oral-monotherapy-shows-positive-results-against-rare-blood-disease/2730214/
Novartis's big bet on sickle cell disease struggles to reach Kenya: Pharma giants are pouring money into new therapies for sickle cell disease but in Kenya ...
swissinfo.ch/eng/sci-tech/africa-s-long-wait-for-a-sickle-cell-cure/47871656
First-ever licensing deal struck for cancer drug: Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukemia treatment ...
english.alarabiya.net/News/world/2022/10/20/First-ever-licensing-deal-struck-for-cancer-drug
Novartis: Scemblix approved in the EU for adults with chronic myeloid leukemia: Novartis (NOVN.S) said on Monday its Scemblix was approved by the European ...
reuters.com/business/healthcare-pharmaceuticals/novartis-scemblix-approved-eu-adults-with-chronic-myeloid-leukemia-2022-08-29/
Short-Termism Is Hurting Companies And Costing Lives: If you were told that your company could bring in more revenue, generate greater earnings ...
forbes.com/sites/markmurphy/2022/09/12/short-termism-is-hurting-companies-and-costing-lives/
Paid articlePaid
Novartis: Goldman Sachs sees huge potential: Novartis shares posted slight losses last week.
deraktionaer.de/artikel/pharma-biotech/novartis-goldman-sachs-sieht-gewaltiges-potenzial-20316696.html
Hotline for pharmacies, approval of leukemia drugs and recalls.
ptaheute.de/aktuelles/2022/09/02/hotline-fuer-apotheken-zulassung-von-leukaemie-mittel-und-rueckrufe
If Your Company Wants Game-Changing Innovations, This Nobel Prize Winner Shares Four Strategies You Must Implement
forbes.com/sites/markmurphy/2022/08/30/if-your-company-wants-game-changing-innovations-this-nobel-prize-winner-shares-four-strategies-you-must-implement/
Paid articlePaid
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics